ClinicalTrials.gg
RecruitingNCT06869096Updated Mar 31, 2026

Chlorhexidine Gluconate Versus Saline for Flushing the Surgical Area During Colorectal Cancer Surgery

An interventional study of Intraoperative area irrigation in Colorectal Cancer, Surgical Site Infection and Chlorhexidine, sponsored by Nanchong Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Nanchong Central Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2024, registered Mar 2025).
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
89th of 894
532 · median 80
Started
2024
with 156 others
No phase
150 of 1,139
81 open now
Primary completion
2026-12
later than 301 of 605 live
Registered
879th of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 89th largest by planned enrollment of the 894 interventional ones that give a count, is one of 157 that started in 2024, is one of 150 with no phase, reaches primary completion later than 301 of the 605 other live ones, and was the 879th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

524 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The aim of this study was to compare the effectiveness of chlorhexidine versus saline in flushing the surgical area during colorectal cancer surgery. The primary outcomes included surgical site infection, postoperative complication rates, et al.

03

Conditions studied

  • Colorectal Cancer
  • Surgical Site Infection
  • Chlorhexidine
  • Complications
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18-85 years,
  2. Patients with surgically resectable colorectal tumors confirmed by CT/MRI before surgery
  3. All patients had a performance status score of 0 or 1 in the Eastern Tumor Cooperative group
  4. American Society of Anesthesiology grade I-III

Exclusion criteria

Exclusion Criteria:

  1. The tumor may have distant
  2. History of previous abdominal surgery
  3. The patient has a history of other malignant tumors diagnosed in the past 5 years and has received radiotherapy and chemotherapy in the past
  4. There are obvious to surgery (obvious abnormal liver and kidney function, pregnancy)
  5. Participated in other clinical trials within the past 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
532 participants (estimated)

Study arms

  • Experimental
    Diabetic rectal cancer patients, chlorhexidine irrigation group

    After colorectal cancer surgery, flush the surgical area with chlorhexidine solution 1 minute before suturing the skin.

    Procedure: Intraoperative area irrigation

  • No intervention
    Diabetic rectal cancer patients, saline irrigation group
  • Experimental
    Diabetic colon cancer patients, chlorhexidine irrigation group

    Procedure: Intraoperative area irrigation

  • No intervention
    Diabetic colon cancer patients, saline irrigation group
  • Experimental
    Non-diabetic rectal cancer patients, chlorhexidine irrigation group

    Procedure: Intraoperative area irrigation

  • No intervention
    Non-diabetic rectal cancer patients, saline irrigation group
  • Experimental
    Non-diabetic colon cancer patients, chlorhexidine irrigation group

    Procedure: Intraoperative area irrigation

  • No intervention
    Non-diabetic colon cancer patients, saline irrigation group

Interventions

  • ProcedureIntraoperative area irrigation

    After colorectal cancer surgery, flush the surgical area with chlorhexidine solution 1 minute before suturing the skin. According to abdominal cavity contamination, bleeding and tumor invasion to determine the flushing time and flush fluid volume. If the abdominal cavity infection is more serious or exudate more, the flushing time can be relatively prolonged. At last, there were no obvious blood residue, tissue fragments and suppurative secretions in abdominal cavity. Ensure that the surgical field of vision is clear, the surface of each organ is smooth, and there is no abnormal exudate.

06

What researchers measure

Primary outcomes

  1. Number of participants with Surgical site infection within 30 days

    Any surgical site infection within 30 days of surgery is classified as superficial incision, deep mouth, or organ space infection according to the U.S. Centers for Disease Control and Prevention standards.

    Time frame: 30 days

Secondary outcomes

  1. Number of participants with Postoperative complication within 30 days

    Including anastomotic fistula, anastomotic hemorrhage, intestinal obstruction, deep vein thrombosis and so on

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 29 months is close to that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 11, 2025
StartActual
Jul 2, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06869096
Lead sponsor
Nanchong Central Hospital
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Jul 2, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion